Acetylsalicylic acid/atorvastatin/ramipril
Combination of | |
---|---|
Acetylsalicylic acid | Antiplatelet |
Atorvastatin | Statin |
Ramipril | ACE inhibitor |
Names | |
Trade names | Iltria, Trinomia, Sincronium, others[1][2] |
Clinical data | |
Main uses | Prevention of heart disease and stroke[3] |
Side effects | Those of the individual components[1] |
Acetylsalicylic acid/atorvastatin/ramipril, also known as aspirin/atorvastatin/ramipril, is a combination medication used to prevent heart disease and stroke.[3] Following a heart attack it decreases the risk of death from heart disease by about a third.[2] It is taken by mouth.[4] The combination is easier to take for some people than the individual components.[4]
Side effects are those of the individual components.[1] It is a combination of acetylsalicylic acid (aspirin), an antiplatelet; atorvastatin, a statin; and ramipril, a ACE inhibitor.[1]
The combination was approved for medical use in parts of Europe and Latin America in 2014.[1][5] As of 2023 it was available in 25 countries.[2] It is not available in the United States as of 2023.[2] It is on the World Health Organization's List of Essential Medicines.[6] Alternative may be manufactured with different statins or ACE inhibitors.[4] The components are generally generic medicines.[4] It is a type of polypill.[7] It costs about €10 to €40 a month as of 2016.[5]
References
- ↑ 1.0 1.1 1.2 1.3 1.4 "Iltria" (PDF). HAS. June 2016. Archived (PDF) from the original on 9 September 2023. Retrieved 8 September 2023. Archived 9 September 2023 at the Wayback Machine
- ↑ 2.0 2.1 2.2 2.3 "World Health Organization Includes the Cardiovascular Polypill in Its List of Essential Medicines After a Groundbreaking Study Led by the President of Mount Sinai Heart | Mount Sinai - New York". Mount Sinai Health System. Archived from the original on 10 August 2023. Retrieved 24 September 2023. Archived 10 August 2023 at the Wayback Machine
- ↑ 3.0 3.1 "eEML - Electronic Essential Medicines List". list.essentialmeds.org. Archived from the original on 9 September 2023. Retrieved 8 September 2023. Archived 9 September 2023 at the Wayback Machine
- ↑ 4.0 4.1 4.2 4.3 "eEML - Electronic Essential Medicines List". list.essentialmeds.org. Archived from the original on 9 September 2023. Retrieved 8 September 2023. Archived 9 September 2023 at the Wayback Machine
- ↑ 5.0 5.1 "Cardiovascular Polypill" (PDF). Wellcome Trust. 2016. Archived (PDF) from the original on 4 February 2023. Retrieved 24 September 2023. Archived 4 February 2023 at the Wayback Machine
- ↑ World Health Organization (2023). The selection and use of essential medicines 2023: web annex A: World Health Organization model list of essential medicines: 23rd list (2023). Geneva: World Health Organization. hdl:10665/371090. WHO/MHP/HPS/EML/2023.02.
- ↑ "'Polypill' helps reduce cardiovascular deaths after heart attack". www.medicalnewstoday.com. 2 September 2022. Archived from the original on 29 May 2023. Retrieved 24 September 2023. Archived 29 May 2023 at the Wayback Machine
- Pages using duplicate arguments in template calls
- Webarchive template wayback links
- Chemical articles with unknown parameter in Infobox drug
- Chemical articles without CAS registry number
- Articles without EBI source
- Chemical pages without ChemSpiderID
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Articles without InChI source
- Articles without UNII source
- Drugs missing an ATC code
- Drugs with no legal status
- Articles containing unverified chemical infoboxes
- Drugs that are a combination of chemicals
- RTT
- World Health Organization essential medicines